{"id":561972,"date":"2021-09-08T07:16:01","date_gmt":"2021-09-08T07:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=561972"},"modified":"2021-09-08T07:16:01","modified_gmt":"2021-09-08T07:16:01","slug":"waldenstrom-macroglobulinemia-epidemiology-forecast-report-2030-waldenstrom-macroglobulinemia-epidemiology-analysis-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/waldenstrom-macroglobulinemia-epidemiology-forecast-report-2030-waldenstrom-macroglobulinemia-epidemiology-analysis-2030-delveinsight_561972.html","title":{"rendered":"Waldenstrom Macroglobulinemia Epidemiology Forecast Report 2030 | Waldenstrom Macroglobulinemia Epidemiology Analysis 2030 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631077344.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Waldenstrom Macroglobulinemia Epidemiology Forecast Report 2030 | Waldenstrom Macroglobulinemia Epidemiology Analysis 2030 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1631077344.png\" alt=\"Waldenstrom Macroglobulinemia Epidemiology Forecast Report 2030 | Waldenstrom Macroglobulinemia Epidemiology Analysis 2030 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8216;Waldenstrom Macroglobulinemia &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Waldenstrom Macroglobulinemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/waldenstrom-macroglobulinemia-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Waldenstrom Macroglobulinemia Epidemiology Forecast, 2030.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Waldenstrom&rsquo;s macroglobulinemia (WM) as lymphoma or cancer of the lymphatic system. It occurs in white blood cells called a B-lymphocyte or B-cell, which normally matures into a plasma cell that manufactures immunoglobulin to help the body fight infection. WM cells have characteristics of both B-lymphocytes and plasma cells and are hence classified as a type of non-Hodgkin&rsquo;s lymphoma called lymphoplasmacytic lymphoma (LPL).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/waldenstrom-macroglobulinemia-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> &lsquo;<strong>Waldenstrom Macroglobulinemia Epidemiology Forecast to 2030<\/strong>&lsquo; <\/a>report delivers an in-depth understanding of the disease, historical and forecasted Waldenstrom Macroglobulinemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/07226199abf44fcc381b08e309ee13ff.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key highlights from the Waldenstrom Macroglobulinemia Epidemiology Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the DelveInsight analysis, the total prevalent cases of Waldenstrom&#8217;s Macroglobulinemia were 32,852 in the 7MM in 2017, which is expected to grow at a CAGR of 0.68% for the study period 2017&ndash;2030.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;The 7MM incident population was estimated to be 3817 cases in 2017, which is expected to grow at a CAGR of 0.79% during the forecast period 2017&ndash;2030.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;As per the DelveInsight analysis, 8247 males and 4123 females were suffering from Waldenstrom&#8217;s Macroglobulinemia in 2017 in the US. These cases are further expected to increase by 2030.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In EU5, the highest incident cases were reported to be in Germany followed by France and the United Kingdom whereas the lowest incident rates were reported in Spain during the period 2017&ndash;2030.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit for more <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/waldenstrom-macroglobulinemia-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Waldenstrom Macroglobulinemia Epidemiology Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Waldenstrom Macroglobulinemia Epidemiology report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Waldenstrom Macroglobulinemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Waldenstrom Macroglobulinemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Waldenstrom Macroglobulinemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides insight into the historical and forecasted patient pool of Waldenstrom Macroglobulinemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report helps to recognize the growth opportunities in the 7MM concerning the patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report assesses the disease risk and burden and highlights the unmet needs of Waldenstrom Macroglobulinemia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides the segmentation of the Waldenstrom Macroglobulinemia epidemiology<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary of Waldenstrom Macroglobulinemia<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Waldenstrom Macroglobulinemia Epidemiology Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Waldenstrom Macroglobulinemia: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Case Reports<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Country Wise-Epidemiology of Waldenstrom Macroglobulinemia&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. About DelveInsight<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/waldenstrom-macroglobulinemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Waldenstrom Macroglobulinemia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;Waldenstrom Macroglobulinemia-Market Insights, Epidemiology, and Market Forecast&mdash;2030&rsquo; report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/waldenstrom-macroglobulinemia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Waldenstrom Macroglobulinemia Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Waldenstrom Macroglobulinemia Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Waldenstrom Macroglobulinemia market. A detailed picture of the Waldenstrom Macroglobulinemia pipeline landscape is provided, which includes the disease overview and Waldenstrom Macroglobulinemia treatment guidelines.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=waldenstrom-macroglobulinemia-epidemiology-forecast-report-2030-waldenstrom-macroglobulinemia-epidemiology-analysis-2030-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=waldenstrom-macroglobulinemia-epidemiology-forecast-report-2030-waldenstrom-macroglobulinemia-epidemiology-analysis-2030-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8216;Waldenstrom Macroglobulinemia &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Waldenstrom Macroglobulinemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/waldenstrom-macroglobulinemia-epidemiology-forecast-report-2030-waldenstrom-macroglobulinemia-epidemiology-analysis-2030-delveinsight_561972.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-561972","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/561972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=561972"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/561972\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=561972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=561972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=561972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}